PAA Laboratories is a developer and manufacturer of specialized and cell culture products such as media, sera, growth supplements and reagents for use in biomedical research and in the production of protein-based pharmaceuticals.
With this acquisition, GE expects to expand its discovery and manufacturing business of biopharmaceuticals including recombinant proteins, antibodies and vaccines.
The acquisition supports GE healthymagination, GE’s global initiative to reduce cost, increase access and improve the quality of healthcare worldwide.
GE Healthcare Life Sciences president and CEO Kieran Murphy said they believe that an integrated approach, where they can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product and reduce time to market.